• BSE
  • NSE
Partner with US Open an Demat Account EIPO Portfolio Tracker Watsapp Play Store App Store

News Details

17/12/2025 16:49

Lupin receives VAI classification from USFDA for Nagpur injectable facility

Lupin on Wednesday said it has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility in Nagpur.

The EIR was issued following an inspection conducted from September 8 to September 16, 2025. A VAI classification indicates that while certain objectionable conditions were observed, the USFDA does not intend to take or recommend any regulatory or administrative action at this stage.